Canadian Cancer Trials Group

This phase III trial is for people with 5 to 15 brain metastases from cancers that are not blood cancers. It compares two treatments: stereotactic radiosurgery (SRS), which delivers high-dose radiation to small spots in one or two days, versus whole brain radiation that avoids th…

This phase 2 trial tests whether combining two drugs, pembrolizumab and brentuximab vedotin, can better shrink or eliminate Hodgkin lymphoma compared to standard chemotherapy (GDP) before a stem cell transplant. About 84 adults with relapsed or refractory classical Hodgkin lympho…

This phase 3 trial is testing whether a shorter, more intense radiation treatment called SBRT works as well as the current standard of external radiation plus a brachytherapy boost for men with unfavorable-risk prostate cancer. About 710 participants will also receive hormone the…

This study looks at whether taking a standard immunotherapy drug (PD-1 inhibitor) on an intermittent schedule works as well as taking it continuously for people with advanced melanoma that cannot be removed by surgery. About 614 participants will be randomly assigned to one of th…

This phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…

This Phase 2 study tests several immunotherapy drug combinations in women with platinum-resistant high-grade serous ovarian cancer, a type that no longer responds to standard chemotherapy. About 60 participants will receive one of five immunotherapy regimens to see which best shr…

This study tests whether giving cancer drugs that target specific genetic changes in a person's tumor can help shrink or control their cancer. It includes 720 adults with advanced solid tumors, lymphoma, or multiple myeloma who have no standard treatment options. Participants rec…

This study is for people with early-stage endometrial cancer whose tumors have certain genetic markers (POLE-mutated or p53 wildtype/NSMP). It tests whether using less intense treatment after surgery can still prevent cancer from coming back while reducing side effects. About 393…

This study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has certain DNA repair gene changes. The trial compares the usual chemo (docetaxel) alone versus docetaxel plus a platinum chemo drug to see if the combination helps patie…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares taking the drugs daratumumab or isatuximab continuously versus stopping after about a year and a half, while continuing other medications. The goal is to see i…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help stop advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or immunotherapy plus L…

This study tests whether adding a drug called zanidatamab to the usual chemotherapy can slow or stop the growth of advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-positive. About 168 adults who have already tried one standard treatment will be random…

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible f…

This study tests whether giving chemotherapy alone before limited surgery works as well as chemotherapy plus radiation for early rectal cancer. The goal is to see if avoiding radiation improves quality of life without harming cancer control. About 250 adults with early-stage rect…

This study is for women with a low-risk type of breast cancer that has spread to nearby lymph nodes or is T3N0. It compares standard care (which includes radiation to the lymph node area) against skipping that extra radiation. The goal is to see if avoiding regional radiation wor…

This study looks at whether a simple blood test that measures cancer DNA (ctDNA) can help doctors decide when to add chemotherapy to standard immunotherapy for lung cancer. About 230 people with advanced lung cancer will take part. The goal is to see if this personalized approach…

This study compares a newer, precise radiation method called stereotactic body radiotherapy (SBRT) with standard radiation therapy for people with advanced head and neck cancer who cannot have curative treatment. About 196 adults will be randomly assigned to one of the two radiat…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This study tests whether adding a third drug (lenvatinib) to a standard two-drug immunotherapy combination (durvalumab + tremelimumab) can better control advanced liver cancer. About 140 adults who have not had prior systemic treatment will be randomly assigned to receive either …

This study looks at whether testing a blood sample for DNA changes can predict which treatment will work best for people with ER+/HER2- metastatic breast cancer that no longer responds to CDK4/6 inhibitors. About 484 participants will provide a blood or tumor sample to check for …

This study tests whether two immunotherapy drugs, botensilimab and balstilimab, help people with advanced colorectal cancer that cannot be removed by surgery and has stopped responding to chemotherapy live longer. About 834 participants will receive either the drug combination or…

This study tests whether using a special imaging scan (SPECT-CT) to guide radiation treatment can safely limit radiation to only one side of the neck in people with oropharyngeal cancer. Currently, standard treatment often involves radiating both sides, which can cause more side …

This study tests whether adding targeted radiotherapy to usual drug therapy can slow the growth or spread of metastatic non-small-cell lung cancer. About 320 adults whose cancer has started to grow in a few spots while on first-line treatment will receive either standard drugs al…

This study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …

This study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …

This study tests whether a newer, more precise type of radiation (SBRT) provides better pain relief than standard radiation for cancer patients with painful bone metastases. About 230 adults with solid tumors and a painful non-spine bone metastasis will receive either SBRT or con…

This study looks at the costs and quality of life for people with high-risk chronic lymphocytic leukemia (CLL) who either start treatment right away or wait. Researchers will track medical visits, tests, and hospital stays over 10 years. The goal is to see which approach gives th…

This study looks at whether cancer patients are willing to share information about their social and economic background, such as income, education, and housing. Researchers want to learn what barriers people face when joining clinical trials and getting healthcare. About 1,000 ad…

This study is testing whether looking at two biological markers (HPV and p53) in early-stage vulvar cancer can help doctors decide the right amount of surgery. Some women may need less surgery, while others may need more. The study will follow 249 participants for 3 years to see …